Blood Management

Society for Advancement of Blood Management (SABM). Available at: www.sabm.org. Accessed July 31, 2006.

American Association of Blood Banks, America's Blood Centers, and American Red Cross., Circular of Information for the Use of Human Blood and Blood Components.

1996, Practice guidelines for blood component therapy. American Society of Anesthesia., Anesthesiology, 84, 732, 10.1097/00000542-199603000-00032

Goodnough, 1991, The variability of transfusion practice in coronary artery bypass surgery., JAMA, 265, 86, 10.1001/jama.1991.03460010086037

Stover, 1998, Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: a 24 institution study., Anesthesiology, 88, 327, 10.1097/00000542-199802000-00009

Ozier, 2003, Institutional variability in transfusion practice for liver transplantation., Anesth Analg, 97, 671, 10.1213/01.ANE.0000073354.38695.7C

Goodnough, 2003, Transfusion medicine: looking towards the future., Lancet, 361s, 161, 10.1016/S0140-6736(03)12195-2

Spahn, 2000, Eliminating blood transfusions: new aspects and perspectives., Anesthesiology, 93, 242, 10.1097/00000542-200007000-00035

Hebert, 1999, for the Transfusion Requirements in Critical Care Investigators and the Canadian Critical Care Trials Group. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care., N Engl J Med, 340, 409, 10.1056/NEJM199902113400601

Carson, 2002, Mortality and morbidity in patients with very low postoperative Hb levels who receive blood transfusion., Transfusion, 42, 812, 10.1046/j.1537-2995.2002.00123.x

Goodnough, 2003, Bloodless medicine., Transfusion, 43, 668, 10.1046/j.1537-2995.2003.00367.x

Hutchinson, 2001, Utilization of technologies to reduce allogeneic blood transfusion in the United States., Transf Med, 11, 79, 10.1046/j.1365-3148.2001.00290.x

Goodnough, 1997, Erythropoietin therapy., N Engl J Med, 336, 933, 10.1056/NEJM199703273361307

Dodd, 2002, Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross donor population., Transfusion, 42, 475, 10.1046/j.1537-2995.2002.00174.x

Centers for Disease Control. Investigations of West Nile virus infections in recipients of blood transfusions.

Goodnough, 1999, Transfusion medicine, part I: blood transfusion., N Engl J Med, 340, 439

Van der Linden, 2001, A standardized multidisciplinary approach reduces the use of allogeneic blood products in patients undergoing cardiac surgery., Can J Anaesth, 48, 894, 10.1007/BF03017357

Goodnough, 2005, Detection, evaluation, and management of anemia in the elective surgical patient., Anesth Analg, 101, 1858, 10.1213/01.ANE.0000184124.29397.EB

Smoller, 1986, Phlebotomy for diagnostic laboratory tests in adults: pattern of use and effect on transfusion requirements., N Engl J Med, 314, 1233, 10.1056/NEJM198605083141906

Brecher, 2001, The rise and fall of preoperative autologous blood donation., Transfusion, 41, 1459, 10.1046/j.1537-2995.2001.41121459.x

Goodnough, 1999, Transfusion medicine, part II: blood conservation., N Engl J Med, 340, 525, 10.1056/NEJM199902183400706

Forgie, 1998, Preoperative autologous donation decreases allogeneic transfusion but increases exposure to all red cell transfusion: results of a meta analysis. International Study of Perioperative Transfusion (ISPOT) Investigators., Arch Intern Med, 158, 610, 10.1001/archinte.158.6.610

Mackey, Association Bulletin 95-4, AABB Position on Testing of Autologous Units.

Kurtz, 1995, A comparison of two surgical techniques for performing mastectomy., Eur J Surg Oncol, 21, 143, 10.1016/S0748-7983(95)90171-X

Braswell, 2001, Reducing operative blood loss during hepatic surgery: from the middle ages to the space age., Curr Surg, 58, 472, 10.1016/S0149-7944(01)00477-9

Wang, 2001, Use of fibrin sealant to reduce bloody drainage and hemoglobin loss after total knee arthroplasty: a brief note on a randomized prospective trial., J Bone Joint Surg, 83A, 1503, 10.2106/00004623-200110000-00007

Schneeberger, 1998, Blood loss in total hip arthroplasty. Lateral position combined with preservation of the capsule versus supine position combined with capsulectomy., Arch Orthop Trauma Surg, 117, 47, 10.1007/BF00703439

Schmied, 1998, The effects of red-call scavenging, hemodilution, and active warming on allogenic blood requirements in patients undergoing hip or knee arthroplasty., Anesth Analg, 86, 387, 10.1213/00000539-199802000-00032

Goodnough, 1998, Acute normovolemic hemodilution should replace the preoperative donation of autologous blood as a method of autologous-blood procurement., Transfusion, 38, 473, 10.1046/j.1537-2995.1998.38598297217.x

Monk, 1995, Acute normovolemic hemodilution is a cost-effective alternative to preoperative autologous blood donation by patients undergoing radical retropubic prostatectomy., Transfusion, 35, 559, 10.1046/j.1537-2995.1995.35795357877.x

Waters, 2000, Amniotic fluid removal during cell salvage in the cesarean section patient., Anesthesiology, 92, 1531, 10.1097/00000542-200006000-00008

Goodnough, 1996, Intraoperative salvage in patients undergoing elective abdominal aneurism repair: an analysis of costs and benefits., J Vasc Surg, 24, 213, 10.1016/S0741-5214(96)70096-4

Hebert, 2001, Is a low transfusion threshold safe in patients with cardiovascular disease?, Crit Care Med, 29, 227, 10.1097/00003246-200102000-00001

Goodnough, 2000, Erythropoietin, iron, and erythropoiesis., Blood, 96, 823, 10.1182/blood.V96.3.823

Goodnough, 1990, Limitations of the erythropoietic response to serial phlebotomy: implications for autologous blood donor programs., J Lab Clin Med, 115, 28

Goodnough, 1992, Preoperative red blood cell production in patients undergoing aggressive autologous blood phlebotomy with and without erythropoietin therapy., Transfusion, 32, 441, 10.1046/j.1537-2995.1992.32592327718.x

Goodnough, 1994, The effect of patient size and dose of recombinant human erythropoietin therapy on red blood cell expansion., J Am Coll Surg, 179, 171

Goodnough, 1995, The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender., J Lab Clin Med, 126, 57

Goodnough, 1998, Erythropoiesis in patients stimulated with erythropoietin: the relevance of storage iron., Vox Sang, 75, 128, 10.1046/j.1423-0410.1998.7520128.x

Goodnough, 1994, Erythropoietin response to anaemia is not altered by surgery or recombinant human erythropoietin therapy., Br J Haematol, 87, 695, 10.1111/j.1365-2141.1994.tb06725.x

Coleman, 1953, Rate of blood regeneration after blood loss., Arch Intern Med, 92, 341, 10.1001/archinte.1953.00240210045006

Crosby, 1958, Treatment of hemochromatosis by energetic phlebotomy: one patient's response to getting 55 liters of blood in 11 months., Br J Haematol, 4, 82, 10.1111/j.1365-2141.1958.tb03836.x

Goodnough, 1996, The use of parenteral iron and recombinant human erythropoietin therapy to stimulate erythropoiesis in patients undergoing repair of hip fracture., Int J Hematol, 1, 163

Finch, 1982, Erythropoiesis, erythropoietin, and iron., Blood, 60, 1241, 10.1182/blood.V60.6.1241.1241

Muirhead, 1995, Evidence-based recommendations for the clinical use of recombinant human erythropoietin., Am J Kidney Dis, 26, S1, 10.1016/0272-6386(95)90645-2

Kaisi, 1988, Evaluation and tolerance of response to iron dextran (Imferon) administered by total dose infusion to pregnant women with iron deficiency anemia., Int J Gynecol Obstet, 26, 235, 10.1016/0020-7292(88)90268-8

Mays, 1976, Intravenous iron dextran therapy in the treatment of anemia occurring in surgical, gynecologic, and obstetric patients., Surg Gynecol Obstet, 143, 381

Hillman, 1969, Control of marrow production by the level of iron supply., J Clin Invest, 48, 454, 10.1172/JCI106002

Henderson, 1969, Characteristics of iron dextran utilization in man., Blood, 34, 357, 10.1182/blood.V34.3.357.357

Hoffman, 2003, A cell-based model of coagulation and the role of factor VIIa., Blood Rev, 17, S1, 10.1016/S0268-960X(03)90000-2

De Gasperi, 2006, Intraoperative use of recombinant activated factor VII (rFVIIa)., Minerva Anestesiol, 72, 489

Chiara, 2006, Treatment of critical bleeding in trauma patients., Minerva Anestesiol, 72, 383

Gowers, 2005, Recombinant activated factor VIIa use in massive transfusion and coagulopathy unresponsive to conventional therapy., Anaesth Intensive Care, 33, 196, 10.1177/0310057X0503300207

Goodnough, 2004, Experiences with recombinant human factor VIIa in patients with thrombocytopenia., Semin Hematol, 41, 25, 10.1053/j.seminhematol.2003.11.006

Lin, 2003, The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings., J Neurosurg, 98, 737, 10.3171/jns.2003.98.4.0737

Heilmann, 2006, Successful treatment of life-threatening bleeding after cesarean section with recombinant activated factor VII., Clin Appl Thromb Hemost, 12, 227, 10.1177/107602960601200213

Karadimov, 2003, Use of activated recombinant factor VII (NovoSeven) during neurosurgery., J Neurosurg Anesthesiol, 15, 330, 10.1097/00008506-200310000-00008

Karkouti, 2005, Recombinant factor VIIa for intractable blood loss after cardiac surgery: a propensity score-matched case control analysis., Transfusion, 45, 26, 10.1111/j.1537-2995.2005.04216.x

Romagnoli, 2006, Small-dose recombinant activated factor VII (NovoSeven) in cardiac surgery., Anesth Analg, 102, 1320, 10.1213/01.ane.0000209023.96418.e5

Friederich, 2003, Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial., Lancet, 361, 201, 10.1016/S0140-6736(03)12268-4

Boffard, 2005, Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel, randomized placebo-controlled, double-blind clinical trials., J Trauma, 59, 8, 10.1097/01.TA.0000171453.37949.B7

Lodge, 2005, Recombinant coagulation factor VIIa in major liver resection: a randomized, placebo-controlled, double-blind clinical trial., Anesthesiology, 102, 269, 10.1097/00000542-200502000-00006

Raobaikady, 2005, Use of activated recombinant coagulation factor VII in patients undergoing reconstruction surgery for traumatic fracture of pelvis or pelvis and acetabulum: a double blind, randomized, placebo-controlled trial., Br J Anaesth, 94, 586, 10.1093/bja/aei102

Goodnough, 2004, Transfusion medicine service policies for recombinant factor VIIa administration., Transfusion, 44, 1325, 10.1111/j.1537-2995.2004.04052.x

O'Connell, 2006, Thromboembolic adverse events after use of recombinant human coagulation factor VIIa., JAMA, 295, 293, 10.1001/jama.295.3.293

Levy, 2006, Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis or severe traumatic injury: review of safety profile., Transfusion, 46, 919, 10.1111/j.1537-2995.2006.00824.x

Levi, 2005, Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review (review)., Crit Care Med, 33, 883, 10.1097/01.CCM.0000159087.85970.38

Shander, 2005, Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven®) therapy., Pharm Ther, 30, 644

Levy, 2004, Hemostatic agents., Transfusion, 44, 58S, 10.1111/j.0041-1132.2004.04173.x

Ozier, 2006, Pharmacological approaches to reducing blood loss and transfusions in the surgical patient., Can J Anaesth, 53, S21, 10.1007/BF03022249

Royston, 1998, Aprotinin versus lysine analogues: the debate continues., Ann Thorac Surg, 65, S9, 10.1016/S0003-4975(98)00071-X

Murkin, 2000, Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement., J Bone Joint Surg Am, 82, 675, 10.2106/00004623-200005000-00008

Levy, 2005, Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation., Am J Health Syst Pharm, 62, S15, 10.2146/ajhp050303

Henry, Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion.

Carless, 2005, Are antifibrinolytic drugs equivalent in reducing blood loss and transfusion in cardiac surgery? A meta-analysis of randomized head-to-head trials., BMC Cardiovasc Disord, 5, 19, 10.1186/1471-2261-5-19

Levi, 1999, Pharmacological strategies to decrease excessive blood loss in cardiac surgery: a meta-analysis of clinically relevant endpoints., Lancet, 354, 1940, 10.1016/S0140-6736(99)01264-7

Engles, 2005, Review and application of serine protease inhibition in coronary artery bypass graft surgery., Am J Health Syst Pharm, 62, S9, 10.2146/ajhp050300

Trasylol® (aprotinin injection) [package insert].

FDA Public Health Advisory-Aprotinin Injection (Marketed as Trasylol).

Multicenter Study of Perioperative Ischemia Research Group,, 2006, The risk associated with aprotinin in cardiac surgery., N Engl J Med, 354, 353, 10.1056/NEJMoa051379

Karkouti, 2006, A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery., Transfusion, 46, 327, 10.1111/j.1537-2995.2006.00724.x

Kikura, 2006, A double-blind, placebo-controlled trial of epsilon-aminocaproic acid for reducing blood loss in coronary artery bypass grafting surgery., J Am Coll Surg, 202, 216, 10.1016/j.jamcollsurg.2005.10.001

Camarasa, 2006, Efficacy of aminocaproic, tranexamic acids in the control of bleeding during total knee replacement: a randomized clinical trial., Br J Anaesth, 96, 576, 10.1093/bja/ael057

Amicar® (aminocaproic acid), injection, oral solution, and tablets [package insert].

Mahdy, 2004, Perioperative systemic haemostatic agents., Br J Anaesth, 93, 842, 10.1093/bja/aeh227

Salzman, 1986, Treatment with desmopressin acetate to reduce blood loss after cardiac surgery: a double-blind randomized trial., N Engl J Med, 314, 1402, 10.1056/NEJM198605293142202

Sagripanti, 2001, Nontransfusional haemostatic agents in the management of bleeding disorders., Intern Med, 9, 10

Moskowitz, 2004, Predictors of transfusion requirements for cardiac surgical procedures at a blood conservation center., Ann Thor Surg, 77, 626, 10.1016/S0003-4975(03)01345-6